On World Cancer Day, we highlighted how Testbed Sweden Precision Health Cancer is revolutionizing cancer care through precision medicine. Our initiative, FOCU·SE, drives basic research, clinical trials, and implementation of precision medicine treatments.

Key highlights:
• SweTrial initiative advancing precision cancer treatment trials
• NASTRO's expanding network of oncological trial units
• Launch of FOCU.SE, a DRUP-like clinical study
• Collaboration with patient organizations and national infrastructure

Supported by Vinnova and Swelife, we unite university hospitals, regulatory authorities, patient organizations, and research institutions. Through PCM4EU and PRIME-ROSE projects, we're connecting with European partners to implement precision cancer medicine.

Välkommen till webinarium om Molecular Tumor Board Portal – beslutsstödsystem för omikdata vid cancerbehandling och kliniska studier. Molecular Tumor Board Portal (MTBP) har utvecklats inom Janne Lehtiös labb vid Karolinska Institutet och används som beslutsstödsystem för att inkludera patienter till studien Basket of Baskets (BoB) som drivs inom samarbetet Cancer Core Europe.

Clinical trials can be used to help prepare a health system to implement PCM at scale – as long as the trials are designed effectively. The Implementation Framework for PCM Clinical Trials has been developed to help researchers design and run trials that ultimately support health systems to implement PCM sustainably and equitably.

Välkommen till webinarium om Molecular Tumor Board Portal – beslutsstödsystem för omikdata vid cancerbehandling och kliniska studier. Molecular Tumor Board Portal (MTBP) har utvecklats inom Janne Lehtiös labb vid Karolinska Institutet och används som beslutsstödsystem för att inkludera patienter till studien Basket of Baskets (BoB) som drivs inom samarbetet Cancer Core Europe.

Lung cancer is the deadliest form of cancer in terms of number of deaths in Sweden, yet a national screening program is still lacking. A new report from IHE - The Swedish Institute for Health Economics, commissioned by Vision Zero Cancer and AstraZeneca, shows that AI can reduce the resource need and costs for radiologists by approximately 80% and enable earlier detection.

The report has been developed as a part of IHE’s partnership in the VINNOVA-funded innovation milieu Test Bed Sweden Precision Health Cancer. This report reviews challenges to standard methods for cost-effectiveness analyses raised in health-economic and clinical oncology literature. It also discusses further considerations and challenges when estimating the value of precision medicine interventions. The report concludes that the methods used in health economics are not dependent on the availability of rigorous phase 3 data to be able to assess cost-effectiveness and support decision-makers by sorting out the consequences of uncertainty in the evidence.

Together with Lif - de forskande läkemedelsföretagen, Business Sweden, Embassy of Sweden in Madrid, Spain, we arranged for the second consecutive year a special evening event during the ESMO congress.

Cancer is a global societal challenge. To meet it, we need to create better conditions for implementing new knowledge, new methods, and interventions. We need to think anew and adopt a holistic perspective on health. We need to collaborate in new ways between healthcare, industry, and civil society.

On April 23rd-24th, Vision Zero Cancer/ SIR will be at the Nordic Precision Medicine Forum in Stockholm and organise a workshop on impact assessment frameworks for Precision Medicine implementation.

The lung cancer policy network speaks to Ebba Hallersjö Hult, Co-founder and Head of Vision Zero Cancer, a mission-oriented innovation hub coordinated by Stockholm School of Economics Institute for Research, Sweden.

A Public-Private Partnership focusing on implementation of precision health in cancer in Sweden is under establishment. SweConnect will be project managed by Vision Zero Cancer in collaboration with Genomic Medicine Sweden (GMS).

Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?

The PRIME-ROSE kick-off took place in Oslo on September 19-20 and gathered around 70 participants from different partners across Europe.

Testbed Sweden Precision Cancer is attending the PRIME-ROSE kick-off in Oslo right now!

We are looking forward to participating at the Nordic Precision Cancer Medicine conference in Oslo during next week.

FOCUSE is an initiative by Testbed Sweden Precision Health Cancer, founded by Vision Zero Cancer, Genomic Medicine Sweden and SciLifeLab, involving regulators, policymakers, payers, researchers, healthcare providers, patient advocates, and industry to drive the implementation of precision health in cancer care.

Testbed Sweden for Precision Health in Cancer is a system demonstrator of how to introduce concrete precision medicine activities into the Swedish healthcare system in a way that is sustainable and just.

Vision Zero Cancer and Testbed Sweden Precision Health Cancer organised two events during Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.

Join us for the EU Cancer Mission Day - Ireland, advancing the fight against cancer and improving lives.